Josh Jennings, an analyst from TD Cowen, reiterated the Buy rating on Senseonics Holdings. The associated price target remains the same with $1.25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors, primarily centered around the positive reception of Senseonics Holdings’ Eversense 365 platform. Recent insights from key opinion leaders (KOLs) in the diabetes field have highlighted the platform’s ability to address common issues associated with competitive continuous glucose monitoring (CGM) systems and previous sensor models from Senseonics. This feedback suggests that Eversense 365 is poised to drive significant growth for the company in the coming years.
Furthermore, an endocrinologist KOL reported a noticeable increase in the adoption of Senseonics’ technology since the launch of Eversense 365. The KOL noted that the system is a strong contender for patients who have faced challenges with other CGM technologies, and there has been a marked rise in the number of patients opting for Eversense 365 implants. This trend is evident across diverse patient demographics, including younger, middle-aged, and older individuals, which supports the potential for broader market penetration and sustained growth for Senseonics.
According to TipRanks, Jennings is a 3-star analyst with an average return of 1.6% and a 47.39% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Dexcom.